One-Time infusion trial aims to tame rebellious immune systems
NCT ID NCT07490951
Summary
This early-stage study is testing a new, one-time treatment called CD19/BCMA CAR-T therapy for people with severe autoimmune diseases that haven't responded well to standard treatments. It will involve about 20 adults with conditions like lupus or rheumatoid arthritis. The main goals are to check if the treatment is safe and to see if it can help control their disease over two years of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Wuhan No.1 Hospital
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.